Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 02, 2014, 12:41:04 AM

Login with username, password and session length


Members
  • Total Members: 23369
  • Latest: donasim
Stats
  • Total Posts: 636852
  • Total Topics: 48340
  • Online Today: 206
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 6
Guests: 147
Total: 153

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Prostratin News?  (Read 1363 times)

0 Members and 1 Guest are viewing this topic.

Offline freewillie99

  • Member
  • Posts: 306
Prostratin News?
« on: March 06, 2009, 10:05:35 AM »
With all the talk lately about "flushing out the reservoirs", it reminded me of Prostratin and it's purported ability to do just that.  Has anyone heard news of this compound lately?  Thanks.
« Last Edit: March 06, 2009, 10:08:29 AM by freewillie99 »
Beware Romanians bearing strange gifts

Offline veritas

  • Member
  • Posts: 1,410
Re: Prostratin News?
« Reply #1 on: March 06, 2009, 02:40:06 PM »

freewillie99,

I think they found something better:

J23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro.

Bedoya LM, Márquez N, Martínez N, Gutiérrez-Eisman S, Alvarez A, Calzado MA, Rojas JM, Appendino G, Muñoz E, Alcamí J.

Biochem Pharmacol. 2009 Mar 15;77(6):965-78. Epub 2008 Dec 3.


Unidad de Inmunopatología del SIDA, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo, km. 2, 28220 Majadahonda, Madrid, Spain.

Existence of virus reservoirs makes the eradication of HIV infection extremely difficult. Current drug therapies neither eliminate these viral reservoirs nor prevent their formation. Consequently, new strategies are needed to target these reservoirs with the aim of decreasing their size. We analysed a series of jatrophane diterpenes isolated from Euphorbia hyberna and we found that one of them, SJ23B, induces the internalization of the HIV-1 receptors CD4, CXCR4 and CCR5 and prevents R5 and X4 viral infection in human primary T cells at the nanomolar range. Moreover, SJ23B is a potent antagonist of HIV-1 latency. Using Jurkat-LAT-GFP cells, a model for HIV-1 latency, we found that prostratin and SJ23B activate HIV-1 gene expression, with SJ23B being at least 10-fold more potent than prostratin. SJ23B did not elicit transforming foci activity in NIH 3T3 cells but is a potent activator of PKCalpha and delta as measured by in vitro kinase assays and by cellular translocation experiments. By using isoform-specific PKC inhibitors we found that cPKCs are critical for SJ23B-induced HIV-1 reactivation. We also showed that both SJ23B-induced IkappaBalpha degradation and NF-kappaB activation were inhibited by the classical PKC inhibitor, Gö6976. Accordingly, SJ23B synergizes with ionomycin to translocate PKCalpha to the plasma membrane and to activate the NF-kappaB pathway. Moreover, SJ23B activates both NF-kappaB and Sp1-dependent transcriptional activities in primary T cells. We have shown that diterpene jatrophanes represent a new member of anti-AIDS agents that could be developed for mitigating HIV reactivation.

Publication Types:

Research Support, Non-U.S. Gov't

Date of Electronic Publication: 2008 Dec 3
Publication Status: ppublish
PMID: 19100719 [PubMed - in process]

Offline tash08

  • Member
  • Posts: 86
Re: Prostratin News?
« Reply #2 on: March 06, 2009, 07:26:25 PM »
AIDS Research Alliance was granted an exclusive license by the National Institutes of Health (NIH) to develop prostratin as an anti-HIV drug targeting viral reservoirs. AIDS Research Alliance was next awarded an NIH grant under the NIH-Development of AIDS Related Therapeutics Program (NIH-DART) to perform pre-clinical studies for prostratin.
AIDS Research Alliance has signed an agreement with a major Contract Research Organization to conduct the remaining pharmacokinetic and toxicology studies of prostratin required by the Food and Drug Administration (FDA) to start testing it in human phase I studies.
This year, ARA continues to work collaboratively with researchers across the country to advance this landmark and pioneering line of research. AIDS Research Alliances hopes to complete all of the necessary pre-clinical studies on prostratin by the beginning of 2010, clearing the way for human clinical trials.

01/04/06-HIV-
03/09/06-HIV+
05/07-Atripla
04/01/10 CD4-681, VL-UD
07/10/10 CD4-450, VL-UD
10/10/10 CD4-473, VL-UD
01/21/11 cd4-522, VL-UD
05/02/11 CD4-638, VL-UD <20 copies Hell yeah!
08/3/12 CD4-806, VL-UD

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.